Liquidia Q4 net income hits USD 14.6 million as FY SG&A rises 93% to USD 157.2 million

Reuters03-05
Liquidia Q4 net income hits USD 14.6 million as FY SG&A rises 93% to USD 157.2 million

Liquidia said FY 2025 net product sales were USD 148.3 million, including USD 90.1 million in Q4 2025, driven by YUTREPIA following its June 2025 U.S. launch. FY 2025 service revenue, net was USD 10.0 million (down 28.6%), primarily related to the Sandoz promotion agreement for Treprostinil Injection. FY 2025 net loss was USD 68.9 million, while Q4 2025 net income was USD 14.6 million; Q4 2025 also delivered positive non-GAAP adjusted EBITDA of USD 27.3 million. Liquidia ended FY 2025 with USD 190.7 million in cash and cash equivalents. On the commercial side, Liquidia reported more than 3,600 unique prescriptions and more than 2,900 patients started on YUTREPIA since launch, with prescription-to-start conversion at or above 85%. The prescriber base rose to about 860. Management said it plans in 2026 to deepen prescriber adoption, grow the sales force, expand YUTREPIA clinical evidence through multiple new studies, and advance L606 into pivotal trials, funded from operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603050630PRIMZONEFULLFEED9666227) on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment